Press Releases
NRx Pharmaceuticala today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Thursday, March 30, 2023.
NRx Pharmaceuticals today announced that it consummated an offering of 3,766,666 shares of common stock and 3,766,666 warrants to purchase common stock at a combined purchase price of $0.75 per share of common stock and associated warrant.
NRx Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,576,911. This patent, issued to Glytech LLC, is exclusively licensed to NeuroRx, Inc., a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international.
NRx Pharmaceuticals today reported the minutes of a Type B meeting with the U.S. Food and Drug Administration’s Division of Psychiatry Products held on January 11, 2023.
NRx Pharmaceuticals, Inc. today reported the recommendations of an independent Data Safety Monitoring Board (DSMB) which reviewed the safety findings of the first fifty enrolled participants in the Company’s phase 2 clinical trial of NRX-101.
NRx Pharmaceuticals, Inc. today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.
NRx Pharmaceuticals, Inc. today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates.
NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals’ wholly owned subsidiary, NeuroRx, Inc.